SAKAR.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 17:59):

Stats
今日成交量	9 771.00
平均成交量	27 241.00
市值	7.43B
EPS	INR0 ( 2024-02-12 )
下一个收益日期	( INR0 ) 2024-05-19
Last Dividend	INR0 ( N/A )
Next Dividend	INR0 ( N/A )
P/E	54.47
ATR14	INR0.656 (0.19%)

音量相关性

長: -0.04 (neutral)

短: 0.11 (neutral)

Signal:(44.125) Neutral

Sakar Healthcare Limited 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sakar Healthcare Limited 相关性 - 货币/商品

0.47
( neutral )

0.41
( neutral )

0.01
( neutral )

0.44
( neutral )

-0.29
( neutral )

-0.46
( neutral )

Sakar Healthcare Limited 财务报表

Annual	2022
营收:	INR1.33B
毛利润:	INR598.12M (44.85 %)
EPS:	INR6.86

FY	2022
营收:	INR1.33B
毛利润:	INR598.12M (44.85 %)
EPS:	INR6.86

FY	2022
营收:	INR1.28B
毛利润:	INR534.12M (41.65 %)
EPS:	INR890.22

FY	2021
营收:	INR947.39M
毛利润:	INR432.46M (45.65 %)
EPS:	INR7.09

Financial Reports:

No articles found.

Sakar Healthcare Limited

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.